Healios K.K. (OTCMKTS:HLOSF – Get Free Report) is anticipated to announce its resultson Thursday, November 12th. Analysts expect Healios K.K. to announce earnings of ($0.0719) per share and revenue of $0.21 million for the quarter.
Healios K.K. Price Performance
OTCMKTS HLOSF opened at $1.80 on Tuesday. Healios K.K. has a 1 year low of $1.80 and a 1 year high of $4.45. The company has a fifty day simple moving average of $1.80 and a 200 day simple moving average of $2.00.
Healios K.K. Company Profile
Healios K.K. is a Japanese biotechnology company focused on developing regenerative medicine and cell therapies. Its research draws on induced pluripotent stem cell (iPSC) technology and somatic stem cell platforms, with the goal of treating serious diseases that have limited treatment options.
The company’s development programs have included HLCM051, a stem cell therapy investigated for conditions such as acute ischemic stroke and acute respiratory distress syndrome, as well as iPSC-based approaches for diseases including retinal disorders.
See Also
- Five stocks we like better than Healios K.K.
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Healios K.K. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healios K.K. and related companies with MarketBeat.com's FREE daily email newsletter.
